Myriad Genetics Company Profile (NASDAQ:MYGN)

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday, August, 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.04. The company had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The company's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.36 earnings per share. View Myriad Genetics' Earnings History.

Myriad Genetics issued an update on its FY18 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.08. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $789.30 million.Myriad Genetics also updated its Q1 guidance to $0.19-0.21 EPS.

10 brokers have issued 1 year target prices for Myriad Genetics' shares. Their predictions range from $15.00 to $26.00. On average, they expect Myriad Genetics' stock price to reach $20.38 in the next year. View Analyst Ratings for Myriad Genetics.

Here are some recent quotes from research analysts about Myriad Genetics stock:

• 1. According to Zacks Investment Research, "Myriad Genetics ended fiscal 2017 on a solid note, with its fourth-quarter numbers exceeding the Zacks Consensus Estimate. The company particularly observed strong growth in EndoPredict and GeneSight testing revenues. Also, the company witnessed a third consecutive quarter of rise in hereditary cancer volumes. We are also upbeat about the receipt of positive final Local Coverage Determination to expand Medicare coverage of the Prolaris test. Also, it received provincial reimbursement in Quebec for EndoPredict. Recently, the company presented positive data for its BRACAnalysis CDx test. Over the last three months, the company has been trading above the broader industry.  On the flip side, a dull operating margin scenario owing to a rise in operating expenses is disappointing. Currency fluctuations and stiff competition are other major headwinds for the company." (8/11/2017)
• 2. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)

Some companies that are related to Myriad Genetics include ACADIA Pharmaceuticals (ACAD), Mallinckrodt PLC (MNK), Patterson Companies (PDCO), Clovis Oncology (CLVS), Molina Healthcare (MOH), ICU Medical (ICUI), NuVasive (NUVA), Opko Health (OPK), FibroGen (FGEN), Insulet Corporation (PODD), Cantel Medical Corp. (CMD), Portola Pharmaceuticals (PTLA), Sage Therapeutics (SAGE), Hutchison China MediTech Limited (HCM), INC Research Holdings (INCR), Chemed Corp. (CHE), LivaNova PLC (LIVN) and Wright Medical Group N.V. (WMGI).

Myriad Genetics' management team includes the folowing people:

• John T. Henderson M.D., Independent Chairman of the Board
• Mark C. Capone, President, Chief Executive Officer, Director
• Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board
• R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer
• Virginia C. Drosos, President of Assurex Health, Inc.
• Alexander Ford, President of Myriad Genetic Laboratories, Inc.
• Ralph L. McDade Ph.D., President of Myriad RBM, Inc
• Bernard F. Tobin, President of Crescendo Bioscience, Inc
• Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary
• Gary A. King, Executive Vice President - International Operations

Myriad Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (14.19%), BlackRock Inc. (13.87%), Vanguard Group Inc. (9.26%), Dimensional Fund Advisors LP (5.04%), State Street Corp (4.54%) and Frontier Capital Management Co. LLC (4.45%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including BB&T Securities LLC, Canada Pension Plan Investment Board, FMR LLC, Acadian Asset Management LLC, Baillie Gifford & Co., Contrarius Investment Management Ltd, BlackRock Inc. and Gotham Asset Management LLC. View Insider Buying and Selling for Myriad Genetics.

Myriad Genetics' stock was bought by a variety of institutional investors in the last quarter, including Thrivent Financial For Lutherans, Dimensional Fund Advisors LP, PDT Partners LLC, Northern Trust Corp, JPMorgan Chase & Co., Bank of Montreal Can, Parametric Portfolio Associates LLC and Pinebridge Investments L.P.. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Myriad Genetics stock can currently be purchased for approximately $28.80.